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Site-directed mutagenesis.Sequence analysis of the class A G protein-coupled receptors (GPCRs) reveals that most of the highly
conserved sites are located in the transmembrane helices. A second level of conservation exists involving
those residues that are conserved as a group characterized by small and/or weakly polar side chains (Ala, Gly,
Ser, Cys, Thr). These positions can have group conservation levels of up to 99% across the class A GPCRs and
have been implicated inmediating helix–helix interactions inmembrane proteins.We have previously shown
that mutation of group-conserved residues present on transmembrane helices H2–H4 in the β2-adrenergic
receptor (β2-AR) can inﬂuence both receptor expression and function. We now target the group-conserved
sites, Gly3157.42 and Ser3197.46, on H7 for structure-function analysis. Replacing Ser3197.46 with smaller
amino acids (Ala or Gly) did not inﬂuence the ability of the mutant receptors to bind to the antagonist
dihydroalprenolol (DHA) but resulted in ~15–20% agonist-independent activity. Replacement of Ser3197.46
with the larger amino acid leucine lowered the expression of the S319L mutant and its ability to bind DHA.
Both the G315A and G315S mutants also exhibited agonist-independent signaling, while the G315L mutant
did not show speciﬁc binding to DHA. These data indicate that Gly3157.42 and Ser3197.46 are stabilizing β2-AR
in an inactive conformation. We discuss our results in the context of van der Waals interactions of Gly3157.42
with Trp2866.48 and hydrogen bonding interactions of Ser3197.46 with amino acids on H1–H2–H7 and with
structural water.inding maximum of the ligand
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G protein-coupled receptors (GPCRs) share a seven transmem-
brane (TM) helix architecture and activate cognate G-proteins in
response to agonist binding. The most extensively studied ligand-
activated GPCR is the β2-adrenergic receptor (β2-AR), which me-
diates physiological responses to epinephrine and norepinephrine.
The β2-AR was the ﬁrst ligand-activated GPCR to be cloned [1], and
the ﬁrst whose crystal structure was determined at high resolution[2]. The crystal structure of β2-AR was solved with the inverse-
agonist carazolol bound and provided a direct comparison with the
crystal structure of the dark, inactive state of rhodopsin, the dim-
light photoreceptor [3,4]. The two structures revealed the positions
of amino acids that are conserved across the family of class A
GPCRs, but have left largely unanswered questions concerning their
contribution to stabilizing the structure of the inactive receptor or
guiding the transition to an active receptor conformation.
Fig. 1 presents a two-dimensional representation of the β2-AR
sequence with the conserved amino acids highlighted by different
colors. There are at least three levels of conservation that can be
considered in understanding the structure and function of a given
receptor or subfamily of receptors within the GPCR superfamily.
The most important set of conserved residues in the class A GPCR
family are the “signature” amino acids with sequence identities of
N70%. There are 15 signature residues in the transmembrane
helices (H1–H7) including the highly conserved (E/D)RY motif on
H3 and NPxxY motif on H7.
The second level of conservation involves the “group-conserved”
residues in the class A GPCR family with conservation of up to 99%
when considered as a group of small and weakly polar residues (Ala,
Fig. 1. Two-dimensional representation of the β2-AR sequence showing amino acid conservation at the three different levels. The receptor has seven transmembrane helices (H1–
H7) and a short amphipathic helix (H8) that lies on the cytoplasmic surface of the membrane. Amino acids are shown in single-letter codes. Red circles denote signature-conserved
residues that include the (E/D)RY and NPxxY motifs, an asparagine (Asn511.50) on H1, aspartic acid on H2 (Asp792.50), three prolines on helices H5 (Pro2115.50), H6 (Pro2886.50) and
H7 (Pro3237.50) and several hydrophobic residues (Leu752.46,Trp1584.50). Blue circles represent small and weakly polar group-conserved residues in the Class A GPCRs excluding the
olfactory subfamily, and green circles subfamily-speciﬁc residues. The residues in gray are between 70% and 90% conserved in the amine receptor subfamily. CL, cytoplasmic loop; CT,
C terminus; EL, extracellular loop; NT, N terminus.
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membrane proteins as key determinants in helix–helix interactions
[5,6]. We have previously suggested that H1–H4 form a tightly packed
core on the basis of the location of the group-conserved positions [7].
The group-conserved residues present onH2, H3 andH4 in β2-AR have
both structural and functional roles [8]. The most signiﬁcant changes
in receptor expression and activity were observed upon replacement
of the amino acids Ser1614.53 and Ser1654.57 on H4. (The amino acid
numbering used in this manuscript incorporates the residue number
from the receptor sequence (e.g. Ser165) and a residue number (e.g.
4.57) from a generic numbering system developed by Ballesteros and
Weinstein [9]). Substitution at Ser1614.53 and Ser1654.57 by larger
residues lowered the expression and activity of the receptor, but did
not affect speciﬁc binding to the antagonist ligand dihydroalprenolol.
Substitution of other group-conserved residues on helices H2–H4 by
larger amino acids lowered receptor activity in the order Ala1283.47,
Ala762.47, Ser1203.39, and Ala782.49 [8].
The third level of conservation includes those residues that have
sequence identities of N90% in the amine subfamily. Each class A GPCR
subfamily contains a set of residues that makes it uniquely able to
respond to its own ligand. For example, Asp1133.32 on H3 is 92%
conserved in the amine subfamily. This residue is the counterion to
the positively charged amine [10]. The next highest conservation
(92%) is Asn3187.45 on H7. Asn3187.45 corresponds to Ser2987.45 in
rhodopsin, a residue that only has 50% conservation in the opsin
subfamily. Other residues that are highly conserved within the amine
subfamily are Asn692.40 (90%), Trp3137.40 (88%) and Tyr3167.43 (82%).
To fully understand the structure and activation mechanism of any
class A GPCR one needs to deﬁne the roles of key residues at each level
of amino acid conservation. Here, we target two group-conserved
residues, Gly3157.42 and Ser3197.46, present on H7. These residues areof particular interest for several reasons. First, they are connected to
two different functional microdomains [11–13], the conserved
aromatic cluster on H6 and the NPxxY motif on H7. Second, they are
ﬂanked by residues that have very high sequence conservation in the
amine subfamily of receptors: Trp3137.40, Tyr3167.43 and Asn3187.45.
Third, while being group-conserved throughout the class A GPCR
family, they have very high sequence identity within the amine
subfamily (69.2% glycine at position 7.42 and 98% serine at position
7.46). To determine the structural and functional roles of these two
group-conserved residues onH7 in theβ2-AR,mutantswere generated
by site-directed mutagenesis and transiently expressed in COS-1 or
HEK293S cells, and then ligand binding assays were performed using
membrane preparations. To elucidate the effect of these mutations on
G-protein signaling, cAMP levels weremeasured following stimulation
by isoproterenol. We discuss the inﬂuence of mutation at Gly3157.42
and Ser3197.46 on receptor structure and stability.
2. Materials and methods
2.1. Materials
The β2-AR ligands, alprenolol, isoproterenol, epinephrine and
salbutamol were purchased from Sigma (St. Louis, MO, USA). Protease
inhibitors and common chemicals were purchased either from Fisher
(Ottawa, ON, Canada) or Sigma. The detergent n-dodecyl-β-D-maltoside
(DDM) was purchased from Anatrace (Maumee, OH, USA). The
monoclonal antibody, rho-1D4, was prepared by the Cell Culture
Center (Minneapolis, MN) from a cell line provided by R.S. Molday
(University of British Columbia, Vancouver, Canada). Fetal bovine
serum was purchased from Sigma and DME High Glucose was from
Invitrogen (Burlington, ON, Canada). The β2-AR antagonist [3H] DHA
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Chalfont, UK). Synthetic oligonucleotides were purchased from
Invitrogen (Carlsbad, CA, USA).
Buffers used were as follows: Phosphate-buffered saline (PBS)
buffer: 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4
(pH 7.4); Buffer A (Lysis buffer), 10 mM Tris–HCl, pH 7.4, containing
protease inhibitors (1 mM EDTA, 10 μg/ml benzamidine, 10 μg/ml
leupeptin, 20 μg/ml soybean trypsin inhibitor, 5 μg/ml aprotinin, and
0.2 mM phenylmethylsulfonyl ﬂuoride); Buffer B (Storage buffer)
50 mM Tris–HCl, pH 7.4, 12.5 mM MgCl2, containing protease
inhibitors as in Buffer A; Buffer C (Binding buffer), 75 mM Tris–HCl,
pH 7.4, 12.5 mM MgCl2, containing protease inhibitors as in Buffer A.
Buffer E (solubilization buffer), 20 mM Tris–HCl (pH 7.4), containing
500 mM NaCl, 10% glycerol, 1% DM and the protease inhibitors as in
Buffer A.
2.2. Construction of mutant hamster β2-AR genes
Mutant hamster β2-AR genes in the plasmid expression vector,
pMT4, were constructed using the Quick-Change mutagenesis kit
(Stratagene, La Jolla, CA, USA) [8]. The DNA sequences of all the
mutated genes were veriﬁed by automated DNA sequencing (MICB
DNA Sequencing Facility, Winnipeg).
2.3. Cell culture and immunoblot analysis
The wild-type β2-AR and mutant genes were expressed in COS-1
cells using a DEAE-dextran based transient transfection method
[14,15]. For transient transfection of HEK293T cells using the plasmid
pMT4, lipofectamine 2000 (Invitrogen) mediated transfection was
used as described by the manufacturer. Membranes were prepared
using Buffers A and B and as described previously [16]. The protein
concentration in the resuspended membrane pellet was determined
using a modiﬁed DC protein assay kit from Bio-Rad Laboratories
(Hercules, CA). Approximately 2.5–5 μg of the total solubilized
membrane protein were resolved by 10% SDS-PAGE and electro-
blotted onto a nitrocellulose membrane. β2-AR was visualized by
immunodetection with the monoclonal antibody, rho-1D4 [16]. The
band at approximately 65 kDa corresponds to the completely
glycosylated receptor [14].
2.4. Radioligand binding assays
These were carried out in Buffer C, using 2–20 μg of membrane
protein and as described earlier [16,17]. Saturation binding assays
were carried out using 0.1–20 nM [3H] DHA. Binding of [3H] DHA in
the presence of 10 μMalprenolol was used as ameasure of nonspeciﬁc
binding. Speciﬁc binding was derived by subtracting nonspeciﬁc
binding from the total binding and is shown in Fig. 7 (supporting
information). Competition binding assays were performed using 3 nM
[3H] DHA and different concentrations of unlabeled agonists (10−2–
10−9 M) and the reactions kept for 2 h at room temperature.
Radioligand binding data obtained from competition curves were
analyzed by non-linear regression analysis to determine the Ki and
EC50 values using PRISM software version 4.03 (GraphPad Software
Inc, San Diego, CA).
2.5. Immunoﬂuorescence microscopy
HEK293T cells were seeded into six-well tissue culture plates
containing sterilized poly-L-lysine (Sigma)-treated glass cover-slips
and transiently transfected with wild-type β2-AR or mutant DNA
according to the aforementioned transfection protocols. Unless
speciﬁed, all steps were carried out room temperature. Cells were
ﬁxed in 3.7% formaldehyde/1x PBS buffer for 15 min, then permea-
blized with 0.05% triton X-100/1x PBS buffer for 30 min. The cellswere washed and blocked with 1x PBS buffer containing 2% bovine
serum albumin (IgG and Protease free) for 1 h. β2-AR was labeled for
90 min using a 1:1000 dilution of the mouse-anti-rho-1D4 monoclo-
nal antibody (C-terminal tagged β2-AR) and a 1:250 dilution of rabbit-
anti-calnexin polyclonal antibody (Abcam, MA, USA; endoplasmic
reticulum marker). The labeled receptor was washed and incubated
with a ﬂuorescent coupled secondary antibody using a 1:500 dilution
of anti-mouse-FITC (Jackson ImmunoResearch labs, PA, USA) and
anti-rabbit-Texas Red (Jackson ImmunoResearch Laboratories, PA,
USA) for 60 min in the dark. The coverslip was washed twice,
mounted with Prolong-antifade-gold (Invitrogen, Molecular probes,
CA, USA) for 15 min and its edges sealed with nail-polish. Represen-
tative cells were selected and visualized using an Olympus BX61
microscope for cytoplasmic or plasma membrane localization.
2.6. Determination of receptor activation by cAMP assays
Functional characterization of the β2-AR was carried out with
HEK293S cells using a commercially available cAMP assay system
(DiscoveRx HitHunter™ cAMP XS+, Freemont, CA). HEK293S cells
were used as these cells show very small changes in endogenous
cAMP upon stimulation with isoproterenol [8,17]. Measurements of
cAMP levels were made according to the directions supplied by the
manufacturer. Brieﬂy, 44 h after transfection HEK293S cells
(100,000 cells/well) were seeded in a 96 well plate and stimulated
for 30 min with concentrations of agonist (−) isoproterenol ranging
from 10−6 M to 10−12 M. Luminescence was read using a Flex
Station 3 plate reader (Molecular Devices, CA, USA). The assays
were carried out a minimum of three times, each in duplicate and
the data were analyzed using PRISM software version 4.03
(GraphPad Software Inc, San Diego, CA). The cAMP values of the
mutants expressed as relative luminescence units (RLUs) were
normalized to that of wild type β2-AR.
2.7. Occluded surface calculations
The occluded surface (OS) method for the analysis of packing
interactions in proteins has been previously described [5,18]. The
method yields packing values of individual amino acids within a
protein. Brieﬂy, a packing value is composed of two parameters, the OS
area and the distribution of distances to occluded atoms. Using
coordinates from a high resolution structure, amolecular dot surface is
calculated for each residue using a 1.4-Å probe. The dot density is
chosen such that each dot represents 0.215 Å2 of the surface area. A
normal is extended radially from each dot until it either intersects the
van der Waals surface of a neighboring atom or reaches a length of
2.8 Å (the diameter of a water molecule). The OS is deﬁned as that
molecular surface area on the originating atom associatedwith normal
that intersect with another atom surface as opposed to reaching the
2.8-Å limit. All other molecular surface area is considered non-
occluded or exposed. The packing value (PV) relates the occluded
surface to the total surface of the residue (sum of occluded and non-
occluded areas). Division by the total molecular surface area
normalizes the packing value to account for various sizes of amino
acid residues. Structural waters are not included in the calculations,
resulting in surface areas that are non-occluded.
2.8. Homology modeling
The homology model of G315L β2-AR was created in Swiss
PDBviewer [19] (http://www.expasy.org/spdbv/) by threading the
G315L β2-AR sequence onto the opsin structure (3CAP). The
resulting structure was energy minimized in vacuo with the
GROMOS96 43B1 parameter set without a reaction ﬁeld. The energy
computations were done with the GROMOS96 implementation of
Swiss-PdbViewer.
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3.1. Inﬂuence of mutations on receptor expression and ligand binding
Table 1 presents the saturation binding data of the antagonist DHA
for the wild-type β2-AR and the Gly3157.42 and Ser3197.46 mutants.
Two types of mutations were made. First, mutations were made to
other group-conserved amino acids, for example, glycine to alanine or
serine to glycine. The hypothesis is that these conservative substitu-
tions will have a minimal effect on receptor folding and ligand
binding. Second, mutations were made to a non-group conserved
amino acidwith a bulky side chain (i.e. leucine). Total binding, speciﬁc
binding and non-speciﬁc binding of DHAweremeasured [16]. Speciﬁc
binding is the difference between the observed total binding and non-
speciﬁc binding. Binding of [3H] DHA in the presence of 10 μM
alprenolol was used as a measure of non-speciﬁc binding.
When compared to the wild-type β2-AR, the G315A mutant
showed a similar afﬁnity for DHA. The G315S mutant exhibited a
higher KD and an increased amount of non-speciﬁc binding. High non-
speciﬁc binding can be due to the improperly folded protein
interfering with the radioligand assay, or else it can also be due to
the mutation perturbing the ligand binding site of the receptor. In
contrast to the receptors with these conservative substitutions, the
G315L mutant failed to bind to DHA in a speciﬁc manner.
The binding afﬁnity of DHA to the β2-AR with mutations at the
group-conserved site Ser3197.46 was similar to the wild-type receptor
for the conservativemutations S319A and S319G, but the KD increased
for the non-group conserved leucine substitution, S319L.
The level of receptor expression was quantiﬁed by immunoblots
and saturation binding assays using DHA (SI Figs. 6 and 7). The Bmax is
higher than wild-type for the S319A and S319G mutants, and
immunoblot analysis showed heterogeneous expression as indicated
by the presence of three predominant bands in the molecular mass
arrange of 45–65 kDa, with none of the low expressing mutants
producing the ~65 kDa band (SI, Fig. 6). Previously, photocrosslinking
of β2-AR expressed in COS-1 cells showed that the band at ~65 kDa
corresponds to the completely glycosylated receptor [14]. Further-
more, low expressing group-conserved mutants present in H2−H4
also did not show the band at ~65 kDa.
Cell surface expression of the receptor is an excellent indicator of
correct protein folding. To elucidate the subcellular localization of the
mutant receptors, immunoﬂuorescence microscopy studies on the
mutants were carried out in the HEK293T cells (Fig. 2). Immunoﬂu-
orescence microscopy showed that the G315A, S319A and S319G
mutants appear to be predominantly localized on the cell surface with
only a small amount of receptor present intracellularly, presumably
due to receptor that is in-transit (Fig. 2). By contrast, a signiﬁcant
amount of the G315S and S319L mutants appear to be retained in the
intracellular compartments, while the G315L mutant is predominant-
ly found localized internally in the cytoplasm (Fig. 2). Cell surface
localization is a strong indicator of correct folding of the G315A, S319A
and S319G mutants because misfolded membrane proteins areTable 1
Summary of DHA binding to the wild type β2-AR and Gly315 or Ser319 mutant
receptors. The values are expressed as the mean±S.E (n=3 to 5 experiments).
Receptor Kd (nM) Bmax (pmol/mg)







a High non-speciﬁc binding (N20% of total binding).
b Not detected (no signiﬁcant speciﬁc binding detected under the assay conditions).typically retained either in the Golgi and/or in the endoplasmic
reticulum by the endoplasmic reticulum quality control system and
targeted for degradation [20].
3.2. Agonist competition assays and Gαs mediated signaling
Table 2 presents the binding of unlabelled agonists to the wild
type β2-AR and mutant receptors as determined by competition with
3 nM [3H] DHA. We characterized the ligand binding properties of
the wild-type β2-AR and the G315A, S319A and S319G β2-AR
mutants with the following β2-AR agonists: (−) isoproterenol (full
agonist), epinephrine (natural, full agonist) and salbutamol (partial
agonist). We could not determine the binding properties of the
G315S, G315L and S319L mutants as these mutants showed high
non-speciﬁc binding under our assay conditions. Since the afﬁnity of
DHA to the wild-type receptor is similar for the G315A, S319A and
S319G mutants (see Table 1), we can estimate the binding afﬁnities
of the various agonists from the competition data in Table 2.
Salbutamol has a lower afﬁnity to the wild-type receptor than either
epinephrine or isoproterenol; i.e. the concentration needed to
displace DHA is 5–6 times greater for salbutamol. The S319A and
S319G mutants showed slight decreases in afﬁnity for all three
agonists. The G315A substitution had the most marked effect in the
competition assay, requiring a 200-fold increase in agonist concen-
tration to displace the DHA antagonist (Table 2).
The agonist competition data for S319A and S319G are in
agreement with the agonist activation of the wild-type and mutant
receptors measured by cAMP assays (Fig. 3). For the measurements
on the Gly315 mutants treated with isoproterenol in a dose-
dependent manner, the relative activity decreased in the order
G315ANG315SNG315L. For the Ser319 mutants, the relative activity
decreased in the order S319ANS319GNS319L. In general, the basal
activity of the mutant receptors was higher than that of the wild-
type β2-AR (indicated by arrows in Fig. 3). The mutants showed
agonist independent or constitutive activity to various degrees, for
the S319A and S319G it was 15–20% of wild type, while for the
G315A and G315S it was 10–15% of wild type. An unexpected
ﬁnding was the G315A mutant exhibited high agonist dependent
cAMP production even though it had the lowest afﬁnity for (−)
isoproterenol of the mutants assayed in Table 2.
3.3. Molecular packing of Gly3157.42
The crystal structure of β2-AR shows Gly3157.42 is tightly packed
against Cys2856.47 and Trp2866.48 on H6 [2] (Fig. 4A). The packing
interaction can be assessed by the method of occluded surfaces [5,18].
Occluded surface calculations show that the packing value for
Gly3157.42 is high (0.65) indicating that the small glycine side chain
does not form a water binding site in β2-AR. For comparison, the
average packing value for amino acids in helices of membrane
proteins is 0.44 [5]. In helical membrane proteins, glycine has the
highest amino acid packing value (0.52), followed by proline (0.51)
and alanine (0.49) [5].
The replacement of Gly3157.42 with amino acids having larger side
chains results in a steric clash with the side chain of Trp2866.48
(packing value 0.56 [5]). Since the glycine side chain is part of the
helix backbone, larger amino acids at position 7.42 can be accommo-
dated by rotation of the Trp2866.48 side chain, which may be coupled
to the rotation of transmembrane helix H6. Fig. 4B shows a model
of the G315Lβ2-AR structure based on homology with the structure of
active opsin. The leucine side chain at position 315 is well packed
against Trp2866.48. For comparison, Fig. 4C and D show the structures
of inactive rhodopsin and active opsin. In the transition from
rhodopsin to opsin, Trp265 moves away from Ala295, whose packing
value decreases from 0.55 to 0.44. Displacement of the highly
Fig. 2. Immunoﬂuorescencemicroscopy showing localization of wild-type β2-AR and the group-conservedmutants expressed in HEK293T cells. Immunoﬂuorescence was performed
with the mouse rho-1D4 antibody (A) and the endoplasmic reticulum marker, rabbit anti-calnexin antibody (B). The mouse rho-1D4 antibody was visualized with anti-mouse-FITC
secondary antibody (green), and the rabbit anti-calnexin antibody was visualized with anti-rabbit-Texas Red secondary antibody (red). Overlays of (A) and (B) are shown in (C).
Yellow arrows show the locations of receptors. In the wild-type, S319A, S319G and G315Amutants, the receptors were predominantly localized at the plasmamembrane, whereas in
G315S, G315L and S319L the receptors appear to be located in intracellular compartments.
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tive activity observed for the Gly3157.42 mutants.
3.4. Molecular packing of Ser3197.46
Occluded surface calculations yield a smaller packing value (0.51)
for Ser3197.46 than for Gly3157.42. Nevertheless, the packing value is
higher than the average packing value for serine in membrane
proteins (0.47) [5] and reﬂects the tightly hydrogen bonded network
surrounding the Ser3197.46 side chain (Fig. 5). The side chain of
Ser3197.46 forms hydrogen bonds with Asp792.50 (3.3 Å) and
Tyr3167.43 (3.1 Å). In addition, Ser3197.46 hydrogen bonds withwater 534 (3.1 Å), a structural water that also coordinates Asp792.50,
Trp2866.48, and Gly3157.42 (Fig. 5B). Replacement of Ser3197.46 with
non-polar residues (S319A, S319G and S319L) results in loss of its
hydrogen bonding interactions.
4. Discussion
We targeted Gly3157.42 and Ser3197.46 because of their position
between two key functional microdomains in β2-AR. Gly3157.42 is in
contact with Cys2856.47 and Trp2866.48 of the conserved CWxP motif
on H6. Ser3197.46 hydrogen bonds directly with the conserved
Asn511.50 on H1 and Asp792.50 on H2, and bridges Trp2866.48 and
Table 2
Summary of competition ligand binding of wild type β2-AR and mutant receptors.
Receptor Ligands (Ki) μM (95% conﬁdence intervals)
Epinephrine (−) Isoproterenol Salbutamol
Wild type 4.9 (3.5–7.0) 4.2 (2.4–7.5) 25 (21–30)
G315A 1014 (372–2760) 658 (304–1237) 1616 (398–5680)
S319A 127 (65–246) 31 (17–56) 204 (85–488)
S319G 141 (68–293) 64 (30–135) 154 (60–394)
Data obtained from determinations of two or more independent transfections and
analyzed by non-linear regression as described under methods. The 95% conﬁdence
intervals for each measurement are indicated in parenthesis. The binding of unlabeled
agonists to β2-AR was determined by competition with the antagonist 3 nM [3H] DHA
as the radioligand.
1175M. Arakawa et al. / Biochimica et Biophysica Acta 1808 (2011) 1170–1178Asn3227.49 of the conserved NPxxY motif on H7 through water
mediated hydrogen bonds. Gly3157.42 and Ser3197.46 are also ﬂanked
by amino acids that have high sequence conservation within the
amine subfamily of receptors (Trp3137.40, Tyr3167.43 and Asn3187.45).
As a result, these group conserved amino acids are strategicallyFig. 3. Characterization of Gαs-mediated signaling of the wild-type and group-conserved
production using transiently transfected HEK293S cells. Shown are the basal (zero concentr
and the Gly315 and Ser319mutants. Arrows indicate an increase in the basal activity of them
type β2-AR activity, and are from at least three independent experiments performed in duppositioned between the ligand-binding site on the extracellular side
of the receptor and the ionic lock on the cytoplasmic side of the
receptor.
4.1. Gly3157.42 functions as a molecular notch to stabilize Trp2866.48 in
an inactive position
Fig. 5A shows the close packing interaction of Gly3157.42 with the
indole ring of Trp2866.48. These residues are 69% and 96% conserved in
the amine receptor subfamily, respectively. We found that the
conservative mutation of Gly3157.42 to alanine exhibits agonist-
independent cAMP production. The constitutive activity suggests that
Gly3157.42 is stabilizing Trp2866.48 in an inactive conformation. This
packing arrangement is similar to the packing of Ala2957.42 against
Trp2656.48 in rhodopsin [21,22] where substitution of Ala2957.42 with
valine results in constitutive activity and leads to autosomal dominant
congenital stationary night blindness [23]. A similarly close packing
interaction between Ala2917.42 and Trp2526.48 is observed in the
recent structure of the CXCR4 receptor, a member of the large
subfamily of GPCRs that bind peptide ligands [24].helix H7 mutants of β2-AR. Receptor activity was determined by measuring cAMP
ation) and agonist (isoproterenol) induced cAMP production of the wild-type receptor
utants over the wild type receptor. The results are expressed as a percentage of the wild
licate.
Fig. 4.Molecular packing of Gly3157.42 and Leu3157.42 in β2-AR. (A) Crystal structure of β2-AR (2RH1) showing van derWaals interaction of Trp2866.48 and Gly3157.42. (B) Homology
model of G315L β2-AR where the G315L β2-AR sequence was threaded onto the structure of active opsin (3CAP) and the resulting structure was energy minimized with 1000 steps
steepest descent. The inactive structure of rhodopsin (C) and the active structure of opsin (D) are shown for comparison.
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switch involved in receptor activation [25], although the recent crystal
structure of active opsin shows only a small displacement of
Trp2656.48 rather than a change in the side chain rotamer angle (see
Fig. 4D). Evidence for large displacement of the Trp2656.48 side chain
in activated rhodopsin comes from NMR measurements showing the
gain of a direct packing interaction between the retinal C19 methyl
group and the Trp2656.48 side chain, in concert with a loss of packing
interactions with the retinal C18 and C20 methyl groups [21,26].
Substitution of larger residues at position 7.42 in the β2-AR would be
expected to displace the conserved tryptophan as suggested by
computational studies of activated β2-AR [27].Fig. 5. Crystal structure of the β2-AR in the region of Gly3157.42 and Ser3197.46. (A) Packing of
steric clash with Trp2866.48 on H6 and is predicted to displace the Trp2866.48 side chain tow
chain hydroxyl group of Ser3197.46 side chain is hydrogen bonded to the carboxyl C(O)OH
(3.1 Å), while the backbone carbonyl of Ser3197.46 makes contact with the side chain NH of
(C) Hydrogen bonding network connecting the indole NH of Trp2866.48 to the amide sid
Trp2866.48 indole NH (3.48 Å), Ser3197.46 CβOH (2.82 Å), Asn3187.45 NH2 (3.11 Å) and Gly31
hydrogen bonded to Asn322 through Wat532. The same overall set of interactions appears
position 7.46 and histidine occurs at position 7.45 [24]. The polar imidizole of histidine is lGly3157.42 is also in close contact with Cys2856.47. Cysteine is
highly conserved at position 6.47; mutation to serine in the β2-AR
shows normal ligand binding, but reduced activity [25,28], while
mutation to threonine results in constitutive activity [25]. The
mechanism of receptor activation in the C285T mutant may involve
a steric clash of the β-branched threonine methyl group with
Gly3157.42 rather than a change in rotamer angle since the
predominant conformer for threonine in α-helices is gauche+ [25],
which is the observed conformer for Cys2856.47 in the carazolol-
bound structure of β2-AR. Moreover, the Cys2856.47 side chain is more
exposed to cysteine reactive reagents in a constitutively activemutant
of β2-AR [29] and upon agonist binding [30]. Together with ourGly3157.42 with Trp2866.48. An increase in size of the amino acid at position 7.42 causes a
ard the extracellular surface. (B) Hydrogen bonding interactions of Ser3197.46. The side
of Asp792.50 (3.3 Å), to the backbone carbonyl of Tyr3167.43 (3.1 Å) and to water 534
Asn511.50 (3.1 Å). Water 534 is shown hydrogen bonded to the backbone of Gly3157.42.
e chain of Asn3227.49. Water 534 in β2-AR mediates hydrogen bonding between the
57.42 (C=O) (3.38 Å). Water 534 is also hydrogen bonded to Wat548, which in turn is
to exist in the recent crystal structure of the CXCR4 receptor where cysteine occurs at
ocated between the conserved indole ring of Trp6.48 and Cys7.46.
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are consistent with a more open structure in the active receptor being
due to displacement of Trp2866.48 from a molecular notch formed by
Gly3157.42.
4.2. Ser3197.46 mediates hydrogen bonding interactions between
Trp2866.48 and Asn3227.49
Ser3197.46 is highly conserved (98%) in the amine subfamily
and is in a key position between Asn511.50, Asp792.50, Trp2866.48,
and Asn3227.49. These residues are all highly conserved across the
class A GPCRs.
Both the backbone carbonyl and side chain hydroxyl groups of
Ser3197.46 form hydrogen bonds that have structural and functional
importance. The Ser3197.46 carbonyl does not form an intra-helical
hydrogen bond due to its position one helix turn above Pro3237.50 of
the conserved NPxxY sequence. The backbone carbonyl of Ser3197.46
forms an inter-helical hydrogen bond with the amide NH2 functional
group of Asn511.50, the most highly conserved residue in the class A
GPCRs. Along with the backbone carbonyl at position 1.46, another
group-conserved residue, this hydrogen bond functions to orient the
conserved Asn511.50 side chain (Fig. 5B) [31].
The Ser3197.46 side chain is in the center of a hydrogen-bonding
network connecting Trp2866.48 to Asn3227.49. Asn3227.49 is part of the
conserved NPxxY motif on H7 that is involved in receptor activation.
We found that the conservative mutation of Ser3197.46 to alanine
results in constitutive activity. Unlike the Gly3157.42 to alanine
mutation in β2-AR and the Ala2957.42 to valine mutation in rhodopsin
that lead to constitutive activity, the S319Amutation does not increase
the molecular volume of the group-conserved side chain, but rather
removes its ability to hydrogen bond. Ser3197.46 is hydrogenbonded to
water 534, a conserved structural water within the transmembrane
core of the receptor. In rhodopsin, water 2015 mediates interaction of
Trp2656.48, Ser2987.45 and Tyr3017.48. In both β2-AR and rhodopsin,
this conserved water is hydrogen bonded to several additional
conserved water molecules that form a shell surrounding the side
chain of Asn7.49. While the details of the structural changes between
Trp6.48 and Asn7.49 have not been determined by crystallography or
NMR spectroscopy in either the β2-AR or rhodopsin, NMR measure-
ments of rhodopsin show that displacement of Trp2656.48 upon
activation weakens the water-mediated hydrogen bond between the
Trp2656.48 indole NH and Asn3027.49 amide side chain [21]. As a result,
motion of Trp2866.48 away from Gly3157.42 in the β2-AR upon agonist
binding would be expected to alter the hydrogen bonding network
illustrated in Fig. 5C.
The idea that conserved structural waters can act as allosteric
regulators of GPCR function was introduced by Palczewski and
colleagues [32]. These authors showed that the interior water
molecules do not exchange with bulk solvent suggesting that
structural waters represent an intrinsic part of the interfaces between
helices H1, H2, H6 and H7. We propose that the structural waters in
combination with the group-conserved residues on these helices (see
Fig. 5A) create an interface that facilitates the rotation of H6 relative to
H7 during activation.
4.3. Interplay between the three levels of amino acid conservation in
class A GPCRs
Fig. 5 presents the core conserved transmembrane region of the β2-
AR to illustrate the interplay between the signature, group-conserved
and subfamily speciﬁc amino acids. Trp2866.48 is sandwiched between
Gly3157.42 and Val1173.36. The residue at position 3.36 on H3 appears
to play a role that parallels that of group-conserved residue 7.42 onH7.
In rhodopsin, residue 3.36 is a glycine, which has very high
conservation (95%) in the rhodopsin subfamily of receptors. Replace-
ment of this glycine with larger residues results in dark activity ofrhodopsin, where the activity is linearly correlated with the residue
volume [33]. In a similar fashion, mutation of the residue at position
3.36 in receptors of the amine subfamily has been shown to modulate
the receptor activity. The speciﬁc residue at this position in the 5HT4
and histamine H1 receptors has been associated with constitutive
(basal) activity, and mutation can either increase or decrease this
activity. For example, in the histamine H1 receptor substitution of the
wild-type serine with cysteine or threonine increases activity, while
substitution with alanine decreases activity [34]. Pardo and co-
workers proposed that when Trp6.48 rotates upon ligand binding,
Ser3.36 forms an interhelical hydrogen bond with Asn7.45 on H7 [34].
Asn7.45 has the second highest level of subfamily conservation in the
amine receptors (92%). Threonine at position 3.36 has the highest
constitutive activity and may be correlated with a preference for the
g+ rotamer. In the 5HT4 receptor, the wild-type residue is threonine
and substitutionwith alanine or serine decreases activity [35]. The role
of the residue at position 3.36 extends beyond the amine and
rhodopsin subfamilies to other class A GPCRs. Schwartz and colleagues
concluded residue 3.36 often inﬂuences the function of the Trp6.48
rotamer toggle switch, but that it acts in a highly context-dependent
manner [27]. In the gherlin peptide hormone receptor, mutation of the
wild-type threonine residue at 3.36 to alanine was found to increase,
rather than decrease, receptor activity [36]. Together, these results
illustrate the interplay between the three levels of class A receptor
conservation: signature conserved (Trp6.48, Asp2.50, Asn7.49),
group-conserved (Cys6.47, Gly/Ala7.42, Ser/Ala7.46), subfamily con-
served (Gly/Ser/Thr/Val3.36 and Asn7.45).
5. Conclusion
We show that the two group-conserved amino acid residues,
Gly3157.42 and Ser3197.46 play important structural and functional
roles in the β2-AR. Gly3157.42 stabilizes Trp2866.48 in the inactive
conformation, while Ser3197.46 is in the center of a hydrogen bonding
network that stretches from Trp2866.48 to Asn3227.49. The hydrogen-
bonding interactions between Trp2866.48 and Asn3227.49 appear to be
strongly coupled. The conservative mutation to alanine of either
Gly3157.42 or Ser3197.46 results in an increase in the basal activity of
the receptor. We propose that the group-conserved residues on H7
along with conserved structural waters create an extended interface
between the transmembrane helices that facilitates the motion of H6
relative to H7 upon receptor activation. These changes would be
encompassedwithin the global toggle switchmechanism proposed by
Schwartz and colleagues [37].
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamem.2011.01.012.
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